Highlights BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Delayed Toronto S.E. Other stock markets 11:17:36 2024-05-21 EDT			5-day change	1st Jan Change
2.03 ^CAD	+8.56%		-29.02%	-73.97%

05-20	Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing	MT
05-15	BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble	05-15	MT
BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting	04-24	MT
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer	04-10	CI
BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR	04-09	MT
BriaCell Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	03-18	CI
BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case	02-07	CI
Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing	02-06	CI
BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	12-28	CI
BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset	12-20	CI
BriaCell Therapeutics Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023	12-14	CI
BriaCell Highlights Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at Breast Cancer Symposium	12-06	MT
BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS	12-06	CI
BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination Regimen	11-30	CI
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS? IND	11-03	CI
BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2023	23-10-25	CI
BriaCell Collaborates With New York Cancer & Blood Specialists for Late-Stage Study of Bria-IMT in Advanced Breast Cancer	23-10-04	MT
BriaCell Therapeutics Corp. Initiates Pivotal Phase 3 Study of Bria-Imt? in Advanced Metastatic Breast Cancer	23-10-03	CI
BriaCell Therapeutics Corp. Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer	23-09-08	CI
Spin off	23-09-04	FA
Briacell Therapeutics Corp. Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate A Clinical Trial of Bria-Imt in High-Risk Early-Stage Triple Negative Breast Cancer	23-08-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Highlights

Filters